All In MedTech

FDA Clearance Tracker · P180051-S001

OCS Heart System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 27, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplementBreakthrough

The decision

FDA number
P180051-S001
Device name
OCS Heart System
Applicant location
Andover, MA
Received
Nov 8, 2021
Decided
Apr 27, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P180051

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code QIK

FDA's approval statement

As written in FDA's record.

Approval for the Organ Care System (OCS) Heart System for expanding the indication to include donation-after-circulatory-death (DCD) donor hearts. The device is indicated for the preservation of donation-after-brain-death (DBD) hearts initially deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of prolonged cold static cardioplegic preservation (e.g., > 4 hours of cross-clamp time). The OCS Heart System is also indicated for the ex vivo reanimation, functional monitoring, and beating-heart preservation of DCD hearts.

Source documents

Other decisions for TransMedics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.